GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
GlaxoSmithKline (GSK) is conducting a Phase 2b clinical study titled A Phase 2b, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Dose Finding Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of GSK1070806 SC Injection in Adult Participants With Moderate to Severe Atopic Dermatitis. The study aims to assess the safety and effectiveness of GSK1070806 in adults with moderate to severe atopic dermatitis, a condition that has previously been treated with medicated topical treatments or biologic therapy.
The intervention being tested is GSK1070806, a drug administered via subcutaneous injection, intended to treat moderate to severe atopic dermatitis. The study includes four experimental groups receiving different doses of GSK1070806 and a placebo group for comparison.
This interventional study uses a randomized, parallel assignment model with double masking, meaning both participants and investigators are unaware of the treatment allocations. The primary purpose of the study is treatment-focused, aiming to establish the optimal dose of GSK1070806.
The study began on November 16, 2023, with an estimated completion date in 2025. The last update was submitted on July 7, 2025, indicating ongoing progress. These dates are crucial for tracking the study’s development and anticipating future results.
The outcome of this study could significantly impact GSK’s stock performance and investor sentiment, as successful results may enhance GSK’s portfolio in dermatological treatments. Competitors in the atopic dermatitis market will be closely monitoring these developments.
The study is currently active but not recruiting, with further details available on the ClinicalTrials portal.